From the standpoint of cancer therapeutics, these data raise the possibility of pharmacologic inhibition of METTL17 function or other genes critical to mitochondrial-derived ATP suppressing tumor growth, and future studies are needed to assess this possibility and its potential to preferentially target tumor cells. This evidence concerns the gene METTL17 and neoplasm.